News

Get the latest on BIO's announcements, positions and views on everything from healthcare to biofuels.

Press Releases

BIO Unveils Seven-Point Plan to Secure America’s…

Action plan outlines the policies needed to ensure that the biotechnology sector remains a driving force for America’s health, prosperity, national security, and geopolitical strengthWASHINGTON (November 10, 2026) - The Biotechnology Innovation…

Learn more

BIO, Biocom, and California Life Sciences Sue to…

Complaint argues HHS and CMS exceeded statutory authority; rule puts patient access, investment in future innovation, and America’s long-term biotechnology leadership at risk.WASHINGTON, DC & SAN DIEGO, CA & SAN FRANCISCO, CA - The…

Learn more

U.S. Bioscience Industry Powers Over $3 Trillion…

WASHINGTON, DC (October 28, 2026) – Today, the Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) released new national and state-level data on the U.S. bioscience industry’s economic impact…

Learn more

Letters, Testimony, & Comments

Browse All

BIO Comment Letter – FDA-2026-D-1257 – Leveraging…

Learn more

BIO Comment Letter – FDA-2026-D-1255 – Safety…

Learn more

BIO Comment Letter – FDA-2026-N-2366 – CNPV Pilot…

Learn more

Amicus Briefs

Browse All

BIO Files Amicus Brief in Case Addressing Anti…

BIO filed an amicus brief in the U.S. Court of Appeals for the District of Columbia Circuit, seeking the reversal of a lower court decision that found plaintiff Vertex Pharmaceuticals’ patient assistance program in violation of the Anti-Kickback…

Learn more

BIO Files Amicus Brief in Delaware Supreme Court…

BIO filed an amicus brief in the Supreme Court of the State of Delaware, urging the Court to exclude Plaintiffs’ expert opinion, thereby ensuring that Delaware’s standard for the admission of such evidence remains consistent with the federal …

Learn more

BIO Files Amicus Briefs Supporting the Lawfulness…

On February 10, 2025, BIO filed an amicus brief in the U.S. District Court for the District of Columbia, supporting the lawfulness of plaintiff Eli Lilly's proposed 340B rebate model. The 340B Drug Pricing Program ("340B"), through which Medicaid…

Learn more